NCT00021749View on ClinicalTrials.gov

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

January 31, 2003

Conditions

Chronic Lymphocytic LeukemiaCLL

Interventions

DRUG

Oblimerson sodium, G3139

Trial Locations (3)

Unknown

Long Island Jewish Medical Center, New Hyde Park

MD Anderson Cancer Center, Houston

San Antonio Cancer Institute, San Antonio

Sponsors

Lead Sponsor

Genta Incorporated

All Listed Sponsors

lead

Genta Incorporated

INDUSTRY